Charles Conway - 23 Nov 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role
Chief Scientific Officer
Signature
/s/ Jim Engelhart, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
23 Nov 2021
Net transactions value
+$393,799
Form type
4
Filing time
26 Nov 2021, 15:26:12 UTC
Previous filing
26 Nov 2021
Next filing
07 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $375,400 +10,000 +166% $37.54* 16,012 23 Nov 2021 Direct
transaction BHVN Common Shares Options Exercise $18,399 +885 +5.5% $20.79* 16,897 23 Nov 2021 Direct
transaction BHVN Common Shares Options Exercise $0 +3,000 +18% $0.000000 19,897 25 Nov 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -10,000 -100% $0.000000* 0 23 Nov 2021 Common Shares 10,000 $37.54 Direct F1
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -885 -2.1% $0.000000 41,727 23 Nov 2021 Common Shares 885 $20.79 Direct F2
transaction BHVN Restricted Share Unit Award Options Exercise $0 -3,000 -50% $0.000000 3,000 25 Nov 2021 Common Shares 3,000 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vested in four equal installments on September 5, 2018, 2019, 2020 and 2021.
F2 The shares underlying this option vest in four equal installments on December 7, 2018, 2019, 2020 and 2021, subject to the reporting person's continued service with the issuer at each vesting date.
F3 Each restricted share unit represents the contingent right to receive one common share of the issuer.
F4 The reporting person was granted 12,000 restricted share units on November 25, 2019, vesting in four equal installments on November 25, 2019, 2020, 2021 and 2022 subject to the reporting person's continued service with the issuer at each vesting date.
F5 Not applicable.